Core Viewpoint - 百心安-B's stock price increased by over 4% following the announcement of the successful market entry and commercialization of the Iberis RDN system in Switzerland [1] Group 1: Company Developments - 百心安-B's subsidiary, Shanghai Antong Medical Technology Co., Ltd., has successfully completed the first commercial procedure using the Iberis RDN system at Basel University Hospital [1] - The procedure reported no complications or adverse events, indicating a positive outcome for the initial commercialization [1] - Antong has formed a strategic partnership with Bosheng International Group to commercialize the Iberis RDN system across multiple regions, including the EU, Asia-Pacific, and Latin America [1] Group 2: Product Information - The Iberis RDN system is the only renal denervation (RDN) product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods [1] - The TRA method enhances the safety, efficacy, and cost-effectiveness of RDN procedures [1] - The ultimate goal of the company is to provide outpatient RDN surgeries for patients worldwide, with the Iberis RDN system having received CE marking in Europe in 2016 [1]
港股异动 | 百心安-B(02185)涨超4% IBERIS® RDN系统在瑞士完成市场准入及首例商业化手术